



Freedom of Information Request: Our Reference CTMUHB_551_25

You asked:

I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions.

Question 1. How many patients were treated in the last 4 months (August to November 2025) by the dermatology department with each of the following products:

- **Abrocitinib**
- **Baricitinib**
- **Dupilumab**
- **Lebrikizumab**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

Please find below a table populated with the information Medicines Management is able to provide at present in relation to question 1. The period the data covers refers to 1st August 2025 to 30th November 25, the latest 4 months available as requested.

Medicine	Number of patients
Abrocitinib	7
Baricitinib	7
Dupilumab	271
Lebrikizumab	17
Tralokinumab	24
Upadacitinib	15
Nemolizumab	10

Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- **Abrocitinib**
- **Baricitinib**
- **Dupilumab**
- **Lebrikizumab**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

***Patients are considered initiated if they have not been treated in the**

previous 8 months with any of the drugs that are part of the named regimen

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.